SMS LIFESCIENCES INDIA LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 814.8 INR | +2.23% |
|
+0.56% | +53.86% |
| May. 27 | SMS Lifesciences India Limited Recommends Final Dividend for the Year 2023-24 | CI |
| May. 27 | SMS Lifesciences India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
SMS Lifesciences India Limited is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph.Eur / IP, Famotidine USP / Ph.Eur / IP, Sildenafil Citrate USP / Ph.Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph.Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. The Company's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center at Sanath Nagar in Hyderabad. The Company's wholly owned subsidiary is Mahi Drugs Private limited.
Sector
Pharmaceuticals
Calendar
2024-08-05
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +53.86% | 28.89M | |
| +51.96% | 803B | |
| -5.77% | 351B | |
| +19.43% | 324B | |
| +11.48% | 303B | |
| +16.96% | 243B | |
| +2.25% | 228B | |
| +11.15% | 217B | |
| +7.36% | 164B | |
| -3.21% | 155B |
- Stock Market
- Equities
- SMSLIFE Stock
- News SMS Lifesciences India Limited
- US FDA Clears SMS Lifesciences' Manufacturing Plant in Kazipally, India
